Natera (NTRA) is down sharply in today’s session as traders focus on renewed insider-selling headlines and unwind risk in a stock that has been priced for strong execution. Recent filings show Executive Chairman Matthew Rabinowitz sold a large block of shares in mid-March, a development that can pressure sentiment even when fundamentals remain intact. (investing.com)

Rabinowitz sold 203,520 shares between March 12 and March 16, 2026 for roughly $38.3 million in proceeds, with transactions executed under a Rule 10b5-1 trading plan. While 10b5-1 plans can reduce the signaling impact versus discretionary sales, repeated large sales can still create a near-term supply/demand imbalance and invite incremental profit-taking. (investing.com)

Natera has been a high-momentum diagnostics name, and selloffs in momentum stocks often accelerate when investors reassess positioning, valuation, and near-term risk after a strong run. Separately, Wall Street has made recent tweaks to targets—such as Morgan Stanley lowering its price target while keeping a bullish rating—which can reinforce the narrative of more limited upside after a big move. (gurufocus.com)

Investors will be watching for additional insider-trade disclosures, updates on Signatera’s regulatory pathway (including the filed PMA for Signatera CDx in bladder cancer), and any reimbursement-related developments that could move near-term revenue expectations. Near-term volatility may remain elevated as the market digests insider supply while awaiting the next clinical/regulatory catalysts. (zacks.com)